4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Globenewswire
- Positive Clinical Data: 4D-710 demonstrated good tolerability and achieved physiologically relevant CFTR expression levels in the AEROW trial, indicating potential clinical benefits across multiple lung function and symptom measures, suggesting its promise as a cystic fibrosis treatment.
- Patient Recruitment Progress: As of December 1, 2025, the AEROW trial has enrolled 16 cystic fibrosis patients, with no new safety events reported across different dose cohorts, underscoring the treatment's safety and efficacy.
- Successful Dose Selection: The 2.5E14 vg dose cohort showed clinically meaningful activity across all endpoints, supporting its selection for the next phase and further optimizing the treatment regimen.
- Future Milestones: The company anticipates completing enrollment of the AEROW Phase 2 Dose-Expansion cohort in H1 2026, further validating the efficacy of 4D-710, with plans to share additional updates in H2 2026.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like FDMT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on FDMT
Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is 29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 8.600
Low
17.00
Averages
29.40
High
38.00
Current: 8.600
Low
17.00
Averages
29.40
High
38.00
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
Continue Reading
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
Continue Reading